long intergenic non-protein coding RNA 2845Genealiases: []
Q-omics provides the consensus-scored LINC02845 profile across patient tissues and cancer cell-line models. LINC02845 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC02845 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, LINC02845 RNA expression shows 7,772 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight ACC, HNSC, and COAD as cancer lineages where LINC02845 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02845 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02845 survival associations across molecular data types. LINC02845 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02845 RNA expression–survival associations across cancer types. High LINC02845 expression shows unfavorable associations in ACC, BRCA, STAD, READ, LIHC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC02845 RNA expression.
This table summarizes LINC02845 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02845. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02845 shows lower tumor expression in HNSC and higher tumor expression in UCEC. The HNSC box plot shows higher LINC02845 RNA expression in normal versus tumor tissue (log2 FC = −0.133, t-test p < 0.001).
This table shows molecular features associated with LINC02845 in patient tissues and cancer cell lines. In patient samples, LINC02845 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
